This article is
- freely available
Vectors for Inhaled Gene Therapy in Lung Cancer. Application for Nano Oncology and Safety of Bio Nanotechnology
Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki 57010, Greece
Pulmonary Department-Interventional Unit, “Ruhrland Klinik”, University of Essen, Essen 45239, Germany
Laboratory of Biochemistry, University of Patras, Patras 25200, Greece
Department of Respiratory diseases, Changhai hospital, Second Military Medical University, Shanghai 200433, China
II Medical Clinic, Hospital of Coburg, University of Wurzburg, Coburg 96450, Germany
Biomaterials Science & Engineering, Department of Materials Science & Engineering, University of Florida, FL 32611, USA
* Author to whom correspondence should be addressed.
Received: 30 July 2012; in revised form: 21 August 2012 / Accepted: 22 August 2012 / Published: 29 August 2012
Abstract: Novel aerosol therapeutic modalities have been investigated for lung cancer. Inhaled gene therapy has presented safety and effectiveness previously in cystic fibrosis. However, safety concerns have been raised regarding the safety of non-viral vectors for inhaled gene therapy in lung cancer, and therefore small steps have been made towards this multifunctional treatment modality. During the last decade, numerous new nanocomplexes have been created and investigated as a safe gene delivery nano-vehicle. These formulations are multifunctional; they can be used as either local therapy or carrier for an effective inhaled gene therapy for lung cancer. Herein, we present current and future perspectives of nanocomplexes for inhaled gene therapy treatment in lung cancer.
Keywords: lung cancer; inhaled gene therapy; non-viral vectors; nanocomplexes; nanobiotechnology
A correction was published on 18 December 2012: http://www.mdpi.com/1422-0067/13/12/17290
(PDF, 129 KB)
The authors wish to add this correction on their paper published in IJMS . The first author’s name is misspelled and the correct name is Paul Zarogoulidis. In addition, the 6th author’s name is incorrect and should be corrected to Wolfgang Hohenforst-Schmidt. These errors have been amended in an amended version of the manuscript, which is available from the International Journal of Molecular Sciences website. The authors and publisher apologize for the inconvenience.
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Zarogouldis, P.; Karamanos, N.K.; Porpodis, K.; Domvri, K.; Huang, H.; Hohenforst-Schimdt, W.; Goldberg, E.P.; Zarogoulidis, K. Vectors for Inhaled Gene Therapy in Lung Cancer. Application for Nano Oncology and Safety of Bio Nanotechnology. Int. J. Mol. Sci. 2012, 13, 10828-10862.
Zarogouldis P, Karamanos NK, Porpodis K, Domvri K, Huang H, Hohenforst-Schimdt W, Goldberg EP, Zarogoulidis K. Vectors for Inhaled Gene Therapy in Lung Cancer. Application for Nano Oncology and Safety of Bio Nanotechnology. International Journal of Molecular Sciences. 2012; 13(9):10828-10862.
Zarogouldis, Paul; Karamanos, Nikos K.; Porpodis, Konstantinos; Domvri, Kalliopi; Huang, Haidong; Hohenforst-Schimdt, Wolfgang; Goldberg, Eugene P.; Zarogoulidis, Konstantinos. 2012. "Vectors for Inhaled Gene Therapy in Lung Cancer. Application for Nano Oncology and Safety of Bio Nanotechnology." Int. J. Mol. Sci. 13, no. 9: 10828-10862.